Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 13, 2023

SELL
$7.65 - $15.51 $200,736 - $406,982
-26,240 Reduced 67.01%
12,921 $190,000
Q3 2022

Nov 14, 2022

SELL
$8.63 - $15.52 $227,676 - $409,448
-26,382 Reduced 40.25%
39,161 $347,000
Q2 2022

Aug 15, 2022

BUY
$8.59 - $20.77 $336,272 - $813,083
39,147 Added 148.31%
65,543 $828,000
Q1 2022

May 12, 2022

BUY
$15.52 - $35.65 $227,973 - $523,662
14,689 Added 125.47%
26,396 $499,000
Q4 2021

Feb 10, 2022

BUY
$28.89 - $35.33 $127,058 - $155,381
4,398 Added 60.17%
11,707 $411,000
Q3 2021

Nov 10, 2021

SELL
$35.66 - $42.94 $185,146 - $222,944
-5,192 Reduced 41.53%
7,309 $268,000
Q2 2021

Aug 11, 2021

BUY
$23.7 - $39.27 $173,460 - $287,417
7,319 Added 141.24%
12,501 $491,000
Q1 2021

May 12, 2021

SELL
$27.01 - $36.8 $2,673 - $3,643
-99 Reduced 1.87%
5,182 $146,000
Q4 2020

Feb 10, 2021

SELL
$27.51 - $34.36 $907 - $1,133
-33 Reduced 0.62%
5,281 $169,000
Q3 2020

Nov 13, 2020

SELL
$25.8 - $34.61 $186,637 - $250,368
-7,234 Reduced 57.65%
5,314 $172,000
Q2 2020

Aug 12, 2020

SELL
$17.65 - $28.05 $53,373 - $84,823
-3,024 Reduced 19.42%
12,548 $346,000
Q1 2020

May 14, 2020

SELL
$15.19 - $29.51 $76,268 - $148,169
-5,021 Reduced 24.38%
15,572 $278,000
Q4 2019

Feb 12, 2020

SELL
$17.17 - $25.95 $20,157 - $30,465
-1,174 Reduced 5.39%
20,593 $516,000
Q3 2019

Nov 12, 2019

BUY
$17.84 - $22.69 $44,600 - $56,725
2,500 Added 12.98%
21,767 $388,000
Q2 2019

Aug 09, 2019

SELL
$22.0 - $31.78 $7,854 - $11,345
-357 Reduced 1.82%
19,267 $424,000
Q1 2019

May 15, 2019

SELL
$21.27 - $30.58 $259,706 - $373,381
-12,210 Reduced 38.36%
19,624 $600,000
Q4 2018

Feb 14, 2019

BUY
$23.09 - $37.69 $735,047 - $1.2 Million
31,834 New
31,834 $735,000

Others Institutions Holding HCM

About HUTCHMED (China) Ltd


  • Ticker HCM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 172,955,008
  • Market Cap $3.11B
  • Description
  • HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...
More about HCM
Track This Portfolio

Track Panagora Asset Management Inc Portfolio

Follow Panagora Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Panagora Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Panagora Asset Management Inc with notifications on news.